News
-
-
PRESS RELEASE
Revenue expected to triple by 2027: Focus on growth markets for medical cannabis and industrial hemp underscores positive outlook for SYNBIOTIC
SYNBIOTIC SE expects to triple revenue by 2027 focusing on growth markets for medical cannabis and industrial hemp. Strategic expansion targets booming sectors -
-
PRESS RELEASE
Successful roadshow continues: SYNBIOTIC keeps expanding its presence in the cannabis and hemp industry
SYNBIOTIC SE expands presence in cannabis and hemp industry through successful roadshow engagements, attracting investors and showcasing at major events. Managing Director Daniel Kruse emphasizes high-profile strategy -
-
-
-
PRESS RELEASE
SYNBIOTIC presents medical cannabis as a pastille for the German market for the first time
SYNBIOTIC SE presents medical cannabis pastilles on the German market for the first time, offering a new, personalized, and effective dosage form. Partnering with BOLDER Arzneimittel, this innovation sets new standards for cannabis therapy -
-
PRESS RELEASE
Quo vadis legalisation: SYNBIOTIC and GOC NEXUS at the International Cannabis Business Conference (ICBC) in Berlin
SYNBIOTIC SE and GOC NEXUS participate in ICBC Berlin to discuss cannabis policy, industry trends, and new medicinal cannabis dosage forms, emphasizing the importance of industrial hemp for job creation and economic growth in Europe
